Table of Contents Author Guidelines Submit a Manuscript
Pain Research and Treatment
Volume 2012, Article ID 612145, 11 pages
Review Article

A Clinical Approach to Neuraxial Morphine for the Treatment of Postoperative Pain

1Department of Anesthesiology, Critical Care and Pain Medicine, Donostia University Hospital, 20014 San Sebastián, Spain
2Pain Relief Unit, Acute and Chronic Pain Management, Donostia University Hospital, 20014 San Sebastián, Spain

Received 4 January 2012; Accepted 16 May 2012

Academic Editor: Howard Smith

Copyright © 2012 Borja Mugabure Bujedo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Opioids are considered a “gold standard” in clinical practice for the treatment of postoperative pain. The spinal administration of an opioid drug does not guarantee selective action and segmental analgesia in the spine. Evidence from experimental studies in animals indicates that bioavailability in the spinal cord biophase is negatively correlated with liposolubility, and is higher for hydrophilic opioids, such as morphine, than lipophilic opioids, such as fentanyl, sufentanil and alfentanil. Epidural morphine sulphate has proven analgesic efficacy and superiority over systemically administered morphine for improving postoperative pain. However, pain relief after a single epidural injection of morphine could last less than 24 hours. Techniques used to administered and prolong opioid epidural analgesia, can be costly and inconvenient. Moreover, complications can arise from indwelling epidural catheterization, particularly in patients receiving anticoagulants. Clinical trials have shown that epidural morphine in the form of extended-release liposome injections (EREM) gives good analgesia for a period of 48 hours, with no need for epidural catheterisation. Intrathecal morphine produces intense analgesia for up to 24 hours with a single shot, and clinical recommendation is to choose the minimum effective dose and do not exceed 300 μg to prevent the delay respiratory depression.